Utility of tolcapone in fluctuating Parkinson’s disease

References

• AdlerCHSingerCO’BrienC1998Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopaArch Neurol551089959708959
   PubMedGoogle Scholar
• BaasHBeiskeAGGhikaJ1997Catechol-O-methyltransferase inhibition with tolcapone reduces the “wearing off” phenomenon and levodopa requirements in fluctuating parkinsonian patientsJ Neurol Neurosurg Psychiatry6342189343116
   PubMed Web of Science ®Google Scholar
• BorgulyaJDa PradaMDingemanseJ1991Ro 40–7592: catecholamine-O-methyltransferase (COMT) inhibitorDrugs Future1671921
   Google Scholar
• CeravoloRPicciniPBaileyDL200218F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson’s diseaseSynapse43201711793426
   PubMed Web of Science ®Google Scholar
• ChapuisSOuchchaneLMetzO2005Impact of the motor complications of Parkinson’s disease on the quality of lifeMov Disord202243015384126
   PubMed Web of Science ®Google Scholar
• CotziasGCVan WoertMHSchifferLM1967Aromatic amino acids and modification of parkinsonismN Engl J Med27637495334614
   PubMed Web of Science ®Google Scholar
• Da PradaMZurcherGKettlerR1991New therapeutic strategies in Parkinson’s disease: inhibition of MAO-B by Ro 19–6327 and of COMT by Ro 40–7592Adv Behav Bio3972332
   Google Scholar
• DavisTLRoznoskiMBurnsRS1995aAcute effects of COMT inhibition on L-DOPA pharmacokinetics in patients treated with carbidopa and selegilineClin Neuropharmacol183337
   PubMed Web of Science ®Google Scholar
• DavisTLRoznoskiMBurnsRS1995bEffects of tolcapone in Parkinson’s patients taking L-dihydroxyphenylalanine/carbidopa and selegilineMov Disord1034951
   PubMed Web of Science ®Google Scholar
• De SantiCGiulianottiPCPeitrabissaA1998Catechol-O-methyl-transferase: variation in enzyme activity and inhibition by entacapone and tolcaponeEur J Clin Pharmacol54215199681662
   PubMed Web of Science ®Google Scholar
• DingemanseJJorgaKMSchmittM1995Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humansClin Pharmacol Ther57508177768073
   PubMed Web of Science ®Google Scholar
• DingemanseJJorgaKZurcherG1995Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitortolcapone and single-dose levodopaBr J Clin Pharmacol40253628527287
   PubMed Web of Science ®Google Scholar
• DingemanseJJorgaKZürcherG1996Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjectsEur J Clin Pharmacol5047558739811
   PubMed Web of Science ®Google Scholar
• DupontEBurgunderJMFindleyLJ1997Tolcapone added to levodopa in stable parkinsonian patients: a double-blind placebo-controlled study. Tolcapone in Parkinson’s Disease Study Group II (TIPS II)Mov Disord12692834
   Web of Science ®Google Scholar
• [EMEA] European Medicines Evaluation Agency2004EMEA public statement on the lifting of the suspension of the marketing authorization for tolcapone (Tasmar) [online]. Accessed 22 May 2006. URL: http://www.emea.eu.int
   Google Scholar
• FactorSAMolhoESFeustelPJ2001Long-term comparative experience with tolcapone and entacapone in advanced Parkinson’s diseaseClin Neuropharmacol24295911586115
   PubMed Web of Science ®Google Scholar
• FahnS1999Parkinson disease, the effect of levodopa, and the ELLDOPA trialArch Neurol565293510328247
   PubMed Web of Science ®Google Scholar
• [FDA] US Food and Drug Administration1998Important drug warning [online]. Accessed 22 May 2006. URL: http://www.fda.gov
   Google Scholar
• [FDA] US Food and Drug Administration2006New monitoring requirements [online]. Accessed 2 November 2006. URL: http://www.fda.gov/medwatch/SAFETY/2006/Feb_PI/Tasmar_PI.pdf
   Google Scholar
• HughesAJBen-ShlomoYDanielSE1992What features improve the accuracy of clinical diagnosis in Parkinson’s disease: a clinicopathologic studyNeurology42114261603339
   PubMed Web of Science ®Google Scholar
• JorgaKMSedekGFottelerB1997Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderlyClin Pharmacol Ther62300109333106
   PubMed Web of Science ®Google Scholar
• JorgaKMKroodsmaJMFottelerB1998Effect of liver impairmenton the pharmacokinetics of tolcapone and its metabolitesClin Pharmacol Ther63646549663179
   PubMed Web of Science ®Google Scholar
• JorgaKFottelerBHeizmannP1999Metabolism and excretion of tolcapone, a novel inhibitor of catechol-O-methyl-transferaseBr J Clin Pharmacol485132010583021
   PubMed Web of Science ®Google Scholar
• KaakkolaS2000Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson’s diseaseDrugs5912335010882160
   PubMed Web of Science ®Google Scholar
• KollerWLeesADoderM2001Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson’s disease patients with motor fluctuationsMov Disord168586611746615
   PubMed Web of Science ®Google Scholar
• KurthMCAdlerCHSt HilaireM1997Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson’s disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trialNeurology488179008498
   PubMed Web of Science ®Google Scholar
• LimousinPPollakPPfefenJP1995Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, (in) Parkinson’s diseaseClin Neuropharmacol18325865
   Web of Science ®Google Scholar
• MyllylaVVJacksonMLarsonJP1997Efficacy and safety of tolcapone in levodopa-treated Parkinson’s disease patients with “wearing-off” phenomena; a multicenter, double-blind, randomized, placebo-controlled trialEur J Neurology4333341
   Web of Science ®Google Scholar
• Novartis Pharmaceuticals USA2000Prescribing information for Comtan® (entacapone) tablets [online]. Accessed 22 May 2006. URL: http//www.comtan.com
   Google Scholar
• OlanowCWWattsRLKollerWC2001An algorithm (decision tree) for the management of Parkinson’s disease (2001): treatment guidelinesNeurology5611 Suppl. 5S1S88
   PubMed Web of Science ®Google Scholar
• OnofrjMThomasAIaconoD2001Switch-over from tolcapone to entacapone in severe Parkinson’s disease patientsEur Neurol461116
   PubMed Web of Science ®Google Scholar
• PahwaRFactorSALyonsKE2006Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of NeurologyNeurology669839516606909
   PubMed Web of Science ®Google Scholar
• RajputAHMartinWSaint-HilaireMH1997Tolcapone improves motor function in parkinsonian patients with the “wearing-off” phenomenon: a double-blind, placebo-controlled, multicenter trialNeurology491066719339691
   PubMed Web of Science ®Google Scholar
• RobertsJWCora-LocatelliGBraviD1994Catechol-O-methyl-tranferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patientsNeurology4426858
   Google Scholar
• ShanDELeeSJChaoLY2001Gait analysis in advanced Parkinson’s disease - effect of levodopa and tolcaponeCan J Neurol Sci2870511252300
   PubMed Web of Science ®Google Scholar
• SuchowerskyOBaileyPPourcherE2001Comparison of two dosages of tolcapone added to levodopa in nonfluctuating patients with PDClin Neuropharmacol421420
   Web of Science ®Google Scholar
• [SWITCH] The Entacapone to Tolcapone Switch Study Investigators2006Entacapone to tolcapone switch: multicenter double-blind, randomized, active-controlled trial in advanced Parkinson’s diseaseMov Disord, Epub Nov 6.
   Google Scholar
• [Tasmar Pl] Valeant Pharmaceuticals International2006Tasmar® (tolcapone) tablets; prescribing information [online]. Accessed 15 May 2006. URL: http//www.tasmar.com
   Google Scholar
• [TSG] Tolcapone Study Group1999Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated Parkinsonian patientsMov Disord1438449918342
   PubMed Web of Science ®Google Scholar
• WatersCHKurthMBaileyP1998Tolcapone in stable Parkinson’s disease: efficacy and safety of long-term treatment. Tolcapone Stable Study GroupNeurology505 Suppl 5S39S45
   Google Scholar
• WattsRKricorianG2005Evaluation of liver-related adverse events with tolcapone: a review of 7-years of worldwide safety dataPresented at the World Congress of Neurology5–11 November 2005Sydney, Australia
   Google Scholar
• YamamotoMYokochiMKunoS1997Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson’s diseaseJ Neural Transm104229369203084
   PubMed Web of Science ®Google Scholar
• ZurcherGColziADa PradaM1990Ro 40–7592: inhibition of COMT in rat brain and extracerebral tissuesJ Neural Transm Suppl3237582089102
   PubMedGoogle Scholar
• ZurcherGDingemanseJDa PradaM1991Ro 40–7592, a potent inhibitor of extracerebral and brain catechol-O-methyltransferase: preclinical and clinical findingsAgnoliACampanellaGNew developments in therapy of Parkinson’s diseaseRome, ItalyJohn Libbey3743
   Google Scholar